Fig. 1: Multiple MGMT fusions in TMZ-treated recurrent gliomas.
From: MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
a Landscape of MGMT hypomethylation, MGMT fusions, DNA hypermutation. b Circos plot showing the identified MGMT fusions. c Structure of the MGMT fusion proteins. Each partner gene is indicated by color, and the narrow bars in SAR1A-MGMT, RPH3A-MGMT, and CTBP2-MGMT mean 5′UTR. d, e Validation of the MGMT fusion genes in positive samples by PCR and Sanger sequencing. The bands in the left panel were validated by Sanger sequencing in the right panel. Limited by specimen availability the validation was performed once. f The genomic rearrangement generating FAM175B-MGMT fusion. WGS whole-genome sequencing. Source data are provided as a Source Data file.
